Skip to main content
Erschienen in: Supportive Care in Cancer 12/2013

01.12.2013 | Original Article

Orphan symptoms in advanced cancer patients followed at home

verfasst von: Sebastiano Mercadante, Giampiero Porzio, Alessandro Valle, Flavio Fusco, Federica Aielli, Claudio Adile, Alessandra Casuccio, On behalf of “Home Care Italy” group (HOCAI group)

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Orphan symptoms are rarely assessed, particularly at home. The aim of this multicenter prospective study was to assess the prevalence of these symptoms and eventual factors possibly associated in advanced cancer patients at admission of a home care program. A prospective study was performed at three home care programs in Italy. Patients' data were collected, including age, sex, diagnosis, and Karnofsky status. Possible contributing factors were analyzed; preexisting neurological diseases, cerebral metastases, hyperthermia, diabetes, a state of dehydration clinically evident and/or oliguria, possible biochemical parameters when available, data regarding recent chemotherapy, opioids and doses, use of neuroleptics, benzodiazepine or anticonvulsants, corticosteroids, anti-inflammatory, and antibiotics were collected. Myoclonus, hiccup, sweating, pruritus, and tenesmus, either rectal or vesical, were assessed, according to a preliminary definition, at time of home care program admission. Three hundred sixty-two patients were surveyed at the three home care programs. Globally, 48 patients presented one or more orphan symptoms in the period taken into consideration, and 7 patients presented more than 1 symptom. One patient presented occasional and diffuse myoclonus. Nineteen patients presented sweating, 13 patients presented pruritus, and 14 patients presented hiccup. Finally, nine patients presented rectal or vesical tenesmus. There was a significant correlation between sweating and transdermal fentanyl use (P = 0.044), fever (P = 0.001), hiccup (P < 0.0005), and vesical tenesmus (P = 0.028). Pruritus was not associated to any factor. Hiccup was associated with gender (males, P = 0.006) and sweating (P < 0.0005). Vesical tenesmus was associated with fever (P = 0.019) and sweating (P = 0.028). Although the symptoms examined have a low prevalence in advanced cancer patients admitted to home care, the distress for patients may be high and deserve further analyses. Given the low prevalence of these symptoms, large studies are needed to find possible associated factors.
Literatur
1.
Zurück zum Zitat Ang SK (2009) Tenesmus, strangury, and malodor. In Palliative Medicine, Walsh D ed. Saunders, 947–950 Ang SK (2009) Tenesmus, strangury, and malodor. In Palliative Medicine, Walsh D ed. Saunders, 947–950
2.
Zurück zum Zitat Bobb B, Lyckholm L, Coyne P (2013) Fever and sweats. In Principles and practice of Palliative Care and Supportive Oncology. Berger AM, Shuster JL, Von Roenn JH eds, Lippincott Williams & Wilkins, 890–93 Bobb B, Lyckholm L, Coyne P (2013) Fever and sweats. In Principles and practice of Palliative Care and Supportive Oncology. Berger AM, Shuster JL, Von Roenn JH eds, Lippincott Williams & Wilkins, 890–93
3.
Zurück zum Zitat Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
4.
Zurück zum Zitat Calsina-Berna A, García-Gómez G, González-Barboteo J, Porta-Sales J (2012) Treatment of chronic hiccups in cancer patients: a systematic review. J Palliat Med 15:1142–1150PubMedCrossRef Calsina-Berna A, García-Gómez G, González-Barboteo J, Porta-Sales J (2012) Treatment of chronic hiccups in cancer patients: a systematic review. J Palliat Med 15:1142–1150PubMedCrossRef
5.
Zurück zum Zitat Ewing G, Brundle C, Payne S, Grande G; National Association for Hospice at Home (2012) The Carer Support Needs Assessment Tool (CSNAT) for Use in Palliative and End-of-life Care at Home: A Validation Study. J Pain Symptom Manage Ewing G, Brundle C, Payne S, Grande G; National Association for Hospice at Home (2012) The Carer Support Needs Assessment Tool (CSNAT) for Use in Palliative and End-of-life Care at Home: A Validation Study. J Pain Symptom Manage
6.
Zurück zum Zitat Gilbert JE, Howell D, King S, Sawka C, Hughes E, Angus H, Dudgeon D (2012) Quality improvement in cancer symptom assessment and control: the Provincial Palliative Care Integration Project (PPCIP). J Pain Symptom Manage 43:663–678PubMedCrossRef Gilbert JE, Howell D, King S, Sawka C, Hughes E, Angus H, Dudgeon D (2012) Quality improvement in cancer symptom assessment and control: the Provincial Palliative Care Integration Project (PPCIP). J Pain Symptom Manage 43:663–678PubMedCrossRef
7.
Zurück zum Zitat Ito S, Liao S (2008) Myoclonus associated with high-dose parenteral methadone. J Palliat Med 11:838–841PubMedCrossRef Ito S, Liao S (2008) Myoclonus associated with high-dose parenteral methadone. J Palliat Med 11:838–841PubMedCrossRef
8.
Zurück zum Zitat Khoshknabi DS (2013) Muscle spasms. In Principles and practice of Palliative Care and Supportive Oncology. Berger AM, Shuster JL, Von Roenn JH eds, Lippincott Williams & Wilkins, 916–21 Khoshknabi DS (2013) Muscle spasms. In Principles and practice of Palliative Care and Supportive Oncology. Berger AM, Shuster JL, Von Roenn JH eds, Lippincott Williams & Wilkins, 916–21
9.
Zurück zum Zitat McCann S, Yaksh TL, von Gunten CF (2010) Correlation between myoclonus and the 3-glucuronide metabolites in patients treated with morphine or hydromorphone: a pilot study. J Opioid Manag 6:87–94PubMedCrossRef McCann S, Yaksh TL, von Gunten CF (2010) Correlation between myoclonus and the 3-glucuronide metabolites in patients treated with morphine or hydromorphone: a pilot study. J Opioid Manag 6:87–94PubMedCrossRef
10.
Zurück zum Zitat Marinella MA (2009) Diagnosis and management of hiccups in the patient with advanced cancer. J Support Oncol 7:122–127PubMed Marinella MA (2009) Diagnosis and management of hiccups in the patient with advanced cancer. J Support Oncol 7:122–127PubMed
11.
Zurück zum Zitat Mercadante S (1998) Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 74:5–9PubMedCrossRef Mercadante S (1998) Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain 74:5–9PubMedCrossRef
12.
Zurück zum Zitat Mercadante S, Valle A, Porzio G, Costanzo BV, Fusco F, Aielli F, Adile C, Fara B, Casuccio A, Home Care—Italy (HOCAI) Group (2011) How do cancer patients receiving palliative care at home die? A descriptive study. J Pain Symptom Manage 42:702–709PubMedCrossRef Mercadante S, Valle A, Porzio G, Costanzo BV, Fusco F, Aielli F, Adile C, Fara B, Casuccio A, Home Care—Italy (HOCAI) Group (2011) How do cancer patients receiving palliative care at home die? A descriptive study. J Pain Symptom Manage 42:702–709PubMedCrossRef
13.
Zurück zum Zitat Nekolaichuk C, Watanabe S, Beaumont C (2008) The Edmonton symptom assessment system: a 15-year retrospective review of validation studies (1991–2006). Palliat Med 22:111–122PubMedCrossRef Nekolaichuk C, Watanabe S, Beaumont C (2008) The Edmonton symptom assessment system: a 15-year retrospective review of validation studies (1991–2006). Palliat Med 22:111–122PubMedCrossRef
14.
Zurück zum Zitat Richardson LA, Jones GW (2009) A review of the reliability and validity of the Edmonton Symptom Assessment System. Curr Oncol 16:55 Richardson LA, Jones GW (2009) A review of the reliability and validity of the Edmonton Symptom Assessment System. Curr Oncol 16:55
15.
Zurück zum Zitat Sarhill N, Mahmoud F (2013) Hiccups and other gastrointestinal symproms. In Palliative care and supportive oncology. WoltesrKluver, Lippincott Williams & Wilkins, Berger AM, Schuster JL, Von Roenn JH eds. 223–237 Sarhill N, Mahmoud F (2013) Hiccups and other gastrointestinal symproms. In Palliative care and supportive oncology. WoltesrKluver, Lippincott Williams & Wilkins, Berger AM, Schuster JL, Von Roenn JH eds. 223–237
16.
Zurück zum Zitat Seccareccia D, Gebara N (2011) Pruritus in palliative care. Can Fam Physic 57:1010–1014 Seccareccia D, Gebara N (2011) Pruritus in palliative care. Can Fam Physic 57:1010–1014
17.
Zurück zum Zitat Smith HS (2013) Hiccups. In Principles and practice of Palliative Care and Supportive Oncology. Berger AM, Shuster JL, Von Roenn JH eds, Lippincott Williams & Wilkins, 895–8. Smith HS (2013) Hiccups. In Principles and practice of Palliative Care and Supportive Oncology. Berger AM, Shuster JL, Von Roenn JH eds, Lippincott Williams & Wilkins, 895–8.
18.
Zurück zum Zitat Yelverton C, McGevna (2013) Pruritus. In Principles and practice of Palliative Care and Supportive Oncology. Berger AM, Shuster JL, Von Roenn JH eds, Lippincott Williams & Wilkins, 309–19 Yelverton C, McGevna (2013) Pruritus. In Principles and practice of Palliative Care and Supportive Oncology. Berger AM, Shuster JL, Von Roenn JH eds, Lippincott Williams & Wilkins, 309–19
19.
Zurück zum Zitat Woelk CJ (2011) Managing hiccups. Can Fam Phys 57:672–675 Woelk CJ (2011) Managing hiccups. Can Fam Phys 57:672–675
Metadaten
Titel
Orphan symptoms in advanced cancer patients followed at home
verfasst von
Sebastiano Mercadante
Giampiero Porzio
Alessandro Valle
Flavio Fusco
Federica Aielli
Claudio Adile
Alessandra Casuccio
On behalf of “Home Care Italy” group (HOCAI group)
Publikationsdatum
01.12.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-2007-0

Weitere Artikel der Ausgabe 12/2013

Supportive Care in Cancer 12/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.